Warfarin treatment in people with rheumatic heart disease and atrial fibrillation
Part of Heart & circulation clinical trials.
This study looks at how well warfarin (a blood thinner) works and is taken by people who have both rheumatic heart disease and atrial fibrillation. It aims to improve treatment safety and outcomes for this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years old or older.
- You must have rheumatic heart disease (a heart condition caused by rheumatic fever).
- You must have atrial fibrillation (an irregular heartbeat) confirmed by a doctor.
- You must have been taking warfarin (a blood thinner) for at least 6 months.
- You must be willing to attend follow-up visits for 12 months and sign a consent form.
- You cannot have a mechanical heart valve, be pregnant, or have another severe illness expected to shorten your life.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a better way to manage warfarin (a blood thinner) for people with atrial fibrillation (an irregular heartbeat). The goal is to improve treatment and help prevent stroke.
This study follows people with atrial fibrillation to see how well blood-thinning medications work and what outcomes they experience over time. It aims to improve treatment guidance for patients with this common heart rhythm condition.
This trial studies whether the blood thinner warfarin is safe and effective for preventing stroke and blood clots in people who have atrial fibrillation and need long-term dialysis. It may help your care team better balance clot prevention against bleeding risk.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This trial follows people with atrial fibrillation to see how long-term blood-thinning treatment affects outcomes over time. It may help determine which long-term approach best lowers stroke and clot risks for patients like you.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
Hear when a new AF trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.